<DOC>
	<DOCNO>NCT01064804</DOCNO>
	<brief_summary>To test relative bioavailability PF-04191834 dose Immediate Release tablet compare solution follow single multiple dosing .</brief_summary>
	<brief_title>To Test The Relative Bioavailability Of PF-04191834 When Dosed As An Immediate Release Tablet Compared With Solution Following Single And Multiple Dosing</brief_title>
	<detailed_description />
	<criteria>Healthy male subject age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Body Mass Index ( BMI ) approximately 17.5 kg/m2 30.5 kg/m2 total body weight &gt; 50 kg ( 110 lb ) . An informed consent document sign date subject legally acceptable representative . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Subjects urinary LTE4 level great equal 30 pg/mg Creatinine screening follow spot urinary collection Cohort 2 . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption ( eg , gastrectomy ) . A positive urine drug screen .</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>